GoodRx Holdings, Inc. (GDRX) Latest Filing Signal

Latest Filing: 10-K  |  Filed Feb 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for GoodRx Holdings, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, GoodRx Holdings, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-4.02%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does GoodRx Holdings, Inc. actually do?
Answer:
GoodRx Holdings, Inc. operates as a consumer-focused digital healthcare platform in the United States, aiming to help Americans save time and money on medications. The company's core offering is a prescription price comparison tool that provides consumers with access to negotiated prices via GoodRx codes, usable at nearly every retail pharmacy nationwide. Beyond prescription savings, GoodRx has expanded its platform to include subscription programs like GoodRx Gold and RxSmartSaver+, condition-specific solutions, and a Pharma Direct offering that partners with manufacturers to integrate affordability solutions. Its value proposition extends to healthcare providers and companies by facilitating medication adherence and providing access to consumers. The company leverages proprietary technology, including a pricing engine and a continuously updated database, to deliver dynamic, geographically relevant prescription pricing.
Question:
What are GoodRx Holdings, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by prescription transactions, where GoodRx earns fees from PBMs or pharmacies for directing consumers to their negotiated prices. Additional revenue streams include subscription offerings, Pharma Direct services, and telehealth services.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required